Monitoring of macrolide resistanceassociated mutations in Mycoplasma genitalium in Russia

Objective. To determine spectrum and prevalence of genetic determinants of resistance to macrolides in Mycoplasma genitalium in a Russian patient population. Materials and Methods. A total of 873 M. genitalium-positive samples from five geographical regions of Russia were investigated over the period of 2009–2019 using the previously developed protocol of real-time polymerase chain reaction (allows detecting any nucleotide substitutions in the 23S rRNA gene of M. genitalium at positions 2058, 2059, and 2611). The results were confirmed using Sanger sequencing. Results. The most frequent mutations associated with resistance to macrolides in M. genitalium were the following: A2058G (60.5%) and A2059G (30.2%). The relatively rare mutations were A2058T (7%) and C2611T (2.3%). In the studied period, there was no trend to increase in frequency of mutations associated with resistance to macrolides. The study results are presented as an open project on the AMRcloud platform (https://amrcloud.net/ru/project/demares/). Conclusions. Our data emphasize a need to introduce regular screening of M. genitalium-positive samples for the presence of macrolide resistance-associated mutations into clinical practice.

[1]  K. Workowski,et al.  Sexually Transmitted Infections Treatment Guidelines, 2021 , 2021, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[2]  K. Muldrew,et al.  Retrospective analysis of infection and antimicrobial resistance patterns of Mycoplasma genitalium among pregnant women in the southwestern USA , 2021, BMJ Open.

[3]  E. Shedko,et al.  Clinical evaluation of commercial PCR assays for antimicrobal resistance in Mycoplasma genitalium and estimation of resistance-mediated mutation prevalence in Moscow and Moscow region , 2021, European Journal of Clinical Microbiology & Infectious Diseases.

[4]  N. Low,et al.  Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. , 2020, The Lancet. Infectious diseases.

[5]  M. Unemo,et al.  Prevalence of Mycoplasma genitalium and Antibiotic Resistance-Associated Mutations in Patients at a Sexually Transmitted Infection Clinic in Iceland, and Comparison of the S-DiaMGTV and Aptima Mycoplasma genitalium Assays for Diagnosis , 2020, Journal of Clinical Microbiology.

[6]  C. Cartwright,et al.  Prevalence of Mycoplasma genitalium infection in women with bacterial vaginosis , 2020, BMC Women's Health.

[7]  N. Luhmann,et al.  HIV and other sexually transmitted infections among female sex workers in Moscow (Russia): prevalence and associated risk factors , 2020, Sexually Transmitted Infections.

[8]  M. Unemo,et al.  Bacterial vaginosis-associated vaginal microbiota is an age-independent risk factor for Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis infections in low-risk women, St. Petersburg, Russia , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[9]  T. Pumarola,et al.  Mycoplasma genitalium and antimicrobial resistance in Europe: a comprehensive review , 2020, International journal of STD & AIDS.

[10]  J. G. Kusters,et al.  Molecular Basis of Antibiotic Resistance in Mycoplasma genitalium. , 2020, International journal of antimicrobial agents.

[11]  O. Zhukova,et al.  The prevalence and type of mutations of in dermatovenereological patients from the Moscow region for 2014‒2018 , 2020 .

[12]  S. Pereyre,et al.  Clinical Evaluation of Three Commercial PCR Assays for the Detection of Macrolide Resistance in Mycoplasma genitalium , 2019, Journal of Clinical Microbiology.

[13]  S. Soni,et al.  High rates of treatment failure for Mycoplasma genitalium among men and women attending a sexual health clinic , 2019, BMJ Sexual & Reproductive Health.

[14]  B. Elmoualij,et al.  Four-color multiplex real-time PCR assay prototype targeting azithromycin resistance mutations in Mycoplasma genitalium , 2019, BMC Infectious Diseases.

[15]  T. Pumarola,et al.  Prevalence of Mycoplasma genitalium and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study , 2019, Sexually Transmitted Infections.

[16]  S. Garland,et al.  Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  I. Edelstein,et al.  The rates of mutations associated with macrolide resistance in Mycoplasma genitalium among patients with non-gonococcal sexually transmitted infections in Smolensk and Tula , 2019, Clinical Microbiology and Antimicrobial Chemotherapy.

[18]  M. Edelstein,et al.  AMRcloud: a new paradigm in monitoring of antibiotic resistance , 2019, Clinical Microbiology and Antimicrobial Chemotherapy.

[19]  H. Fifer,et al.  Mycoplasma genitalium: A Review. , 2019, Microbiology.

[20]  А. В. Романов,et al.  Клинический случай неуспеха терапии джозамицином у пациента с уретритом, вызванным Mycoplasma genitalium , 2018 .

[21]  J. Ong,et al.  Mycoplasma genitalium: an important sexually transmitted infection comes into focus , 2018, Sexually Transmitted Infections.

[22]  M. Unemo,et al.  Macrolide and fluoroquinolone resistance in Mycoplasma genitalium in two Swedish counties, 2011–2015 , 2018, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[23]  J. G. Kusters,et al.  Mycoplasma genitalium in Spain: prevalence of genital infection and frequency of resistance to macrolides. , 2017, Enfermedades infecciosas y microbiologia clinica.

[24]  A. Bahador,et al.  Improvement of semen parameters after antibiotic therapy in asymptomatic infertile men infected with Mycoplasma genitalium , 2018, Infection.

[25]  S. Sethi,et al.  Mycoplasma genitalium infections: current treatment options and resistance issues , 2017, Infection and drug resistance.

[26]  H. Wiesenfeld,et al.  Mycoplasma genitalium in Women: Current Knowledge and Research Priorities for This Recently Emerged Pathogen , 2017, The Journal of infectious diseases.

[27]  S. Philip,et al.  P2.05 A silent epidemic: the prevalence, incidence and persistence of mycoplasma genitalium in young asymptomatic women in the united states , 2017, Sexually Transmitted Infections.

[28]  M. Unemo,et al.  Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia , 2017, PloS one.

[29]  S. Garland,et al.  Prospective Evaluation of ResistancePlus MG, a New Multiplex Quantitative PCR Assay for Detection of Mycoplasma genitalium and Macrolide Resistance , 2017, Journal of Clinical Microbiology.

[30]  S. Garland,et al.  Azithromycin 1.5g Over 5 Days Compared to 1g Single Dose in Urethral Mycoplasma genitalium: Impact on Treatment Outcome and Resistance , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  S. Resch,et al.  Costing of National STI Program Implementation for the Global STI Control Strategy for the Health Sector, 2016-2021 , 2017, PloS one.

[32]  S. Pereyre,et al.  Evaluation of a Commercial Multiplex Quantitative PCR (qPCR) Assay for Simultaneous Detection of Mycoplasma genitalium and Macrolide Resistance-Associated Mutations in Clinical Specimens , 2016, Journal of Clinical Microbiology.

[33]  M. Cusini,et al.  2016 European guideline on Mycoplasma genitalium infections , 2016, Journal of the European Academy of Dermatology and Venereology.

[34]  W. I. van der Meijden,et al.  2016 European guideline on the management of non-gonococcal urethritis , 2016, International journal of STD & AIDS.

[35]  N. Anisimova,et al.  The Aexperience of the Organization and the Screening of Pregnant Women for the Purpose of Detecting Sexually Transmitted Infections, in the Framework of the Regional Program of the Tula Region , 2015 .

[36]  David Bruce Lewis,et al.  Mycoplasma genitalium infection: current treatment options, therapeutic failure, and resistance-associated mutations , 2015, Infection and drug resistance.

[37]  E. Smit,et al.  Prevalence of Trichomonas vaginalis, Mycoplasma genitalium and Ureaplasma urealyticum in men with urethritis attending an urban sexual health clinic , 2015, International journal of STD & AIDS.

[38]  M. Unemo,et al.  Treatment efficacy, treatment failures and selection of macrolide resistance in patients with high load of Mycoplasma genitalium during treatment of male urethritis with josamycin , 2015, BMC Infectious Diseases.

[39]  P. Azzopardi,et al.  Asymptomatic Mycoplasma genitalium infection amongst marginalised young people accessing a youth health service in Melbourne , 2014, International journal of STD & AIDS.

[40]  M. Unemo,et al.  Guidelines for the laboratory diagnosis of mycoplasma genitalium infections in East European countries. , 2010, Acta dermato-venereologica.

[41]  J. Jensen,et al.  Tetracycline treatment does not eradicate Mycoplasma genitalium , 2003, Sexually transmitted infections.

[42]  S. Pereyre,et al.  Mutations in 23S rRNA Account for Intrinsic Resistance to Macrolides in Mycoplasma hominis and Mycoplasma fermentans and for Acquired Resistance to Macrolides in M. hominis , 2002, Antimicrobial Agents and Chemotherapy.